PET Imaging Study Maps Serotonin Receptor Changes in Parkinson's Disease
Completed French trial uses advanced brain imaging to track 5-HT4 serotonin receptors in Parkinson's patients, linking genetics to cognitive and mood changes.
Summary
A completed exploratory study from Hospices Civils de Lyon used PET brain imaging to examine how serotonin 5-HT4 receptors are expressed in people with moderate-stage Parkinson's disease. Researchers compared motor, cognitive, and emotional changes in Parkinson's patients against healthy controls. Using the radioligand [11C]SB207145, they mapped receptor levels across brain regions. The study also investigated whether specific genetic variants — the 5-HTTLPR polymorphism in the serotonin transporter gene and the BDNF Val66Met variant — influence how strongly these receptors are expressed. This work aims to shed light on the serotonergic mechanisms underlying the non-motor symptoms of Parkinson's, such as depression and cognitive decline, which are often undertreated and significantly impact quality of life.
Detailed Summary
Parkinson's disease is far more than a movement disorder. Depression, anxiety, and cognitive decline affect a large proportion of patients, yet the biological pathways driving these non-motor symptoms remain poorly understood. This exploratory study sought to fill a critical gap by examining the serotonin 5-HT4 receptor system — a target with known roles in mood, cognition, and gut-brain signaling — in patients at a moderate stage of the disease.
Researchers at Hospices Civils de Lyon enrolled Parkinson's patients and healthy control subjects for a comprehensive assessment covering motor function, cognition, and affective state. The centerpiece of the study was PET imaging using [11C]SB207145, a highly specific radioligand that binds to 5-HT4 receptors and allows precise, in-vivo quantification of receptor density across brain regions.
Beyond receptor mapping, the team examined how genetic variation shapes the serotonergic landscape. Specifically, they analyzed two polymorphisms: 5-HTTLPR, a variant in the serotonin transporter (SERT) gene linked to anxiety and depression risk, and BDNF Val66Met, a variant affecting brain-derived neurotrophic factor secretion that influences neuroplasticity and cognitive resilience.
The trial has been completed, but results are not yet publicly available. If 5-HT4 receptor expression is found to be altered in Parkinson's — and if genetic variants modulate this — it could point toward personalized treatment strategies targeting the serotonin system to address depression and cognitive symptoms.
This research is clinically significant because serotonergic dysfunction in Parkinson's is increasingly recognized but rarely targeted therapeutically. Understanding receptor-level changes and their genetic determinants may inform future drug development and help clinicians identify which patients are most vulnerable to non-motor decline. Full results are needed before clinical conclusions can be drawn.
Key Findings
- PET imaging with [11C]SB207145 quantified 5-HT4 serotonin receptor levels in moderate-stage Parkinson's patients versus healthy controls.
- Study examined whether 5-HTTLPR and BDNF Val66Met genetic variants modulate 5-HT4 receptor expression in the brain.
- Motor, cognitive, and affective symptoms were all assessed, linking brain imaging to clinical function.
- Trial is completed, potentially yielding the first detailed in-vivo 5-HT4 receptor map specific to Parkinson's disease.
- Findings could identify new serotonin-based treatment targets for non-motor Parkinson's symptoms like depression and cognitive decline.
Methodology
This is a completed exploratory observational study comparing Parkinson's patients at a moderate disease stage to healthy controls using PET imaging with the specific radioligand [11C]SB207145. Participants also underwent neuropsychological assessment and biological sampling for genetic analysis of 5-HTTLPR and BDNF Val66Met polymorphisms. No therapeutic interventions were tested; the study was purely investigational.
Study Limitations
This summary is based on the abstract and trial registration only, as full results are not publicly available; no outcome data can be reported. As an exploratory study without a therapeutic intervention, findings will be hypothesis-generating rather than practice-changing. Sample size details and specific endpoints are not disclosed in the available registration information.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: